Kidney-Glomerular Targeted Immunotherapy Using Bifunctional Molecules

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Glomerular diseases cause damage to the filters in the kidneys, leading to leakage of red blood cells and protein into the urine and accumulation of waste products, and current treatments are inadequate in effectively addressing this chronic condition.

Innovation Solution

Development of kidney-glomerular targeted immunotherapy using antibodies or antigen binding fragments that specifically target COL4A3, COL4A4, or COL4A5 proteins, combined with complement modulators like CD55, CD59, or CR1 to modulate the immune response and prevent damage.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If current treatments are used for glomerular diseases, then general immune suppression is achieved, but kidney-glomerular specific protection is not provided and side effects occur

Engineering Contradiction:

Improvetreatment effectivenessVSAvoidside effects

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent applies local quality by designing a bifunctional molecule where one end targets glomerular-specific antigens (COL4A3, COL4A4, or COL4A5 proteins in the glomerular basement membrane) while the other end provides complement modulation. This ensures the therapeutic effect is localized specifically to the glomeruli rather than causing systemic immune suppression, thereby improving treatment effectiveness while reducing harmful side effects.

Inventive Principle:

Principle #3Local quality

Solution Approach 2:

The patent uses a bifunctional molecule as an intermediary that bridges the gap between specific antigen recognition and complement modulation. The molecule consists of an antibody portion that binds to glomerular-specific antigens and a complement regulatory protein portion (such as CD55, CD59, CR1, or DCP) that modulates complement activation. This intermediary structure enables targeted therapy at the glomerular level without requiring systemic immune suppression.

Inventive Principle:

Principle #24Intermediary (Mediator)

2Reliability

If targeted immunotherapy is developed, then kidney-glomerular specific protection is achieved, but treatment complexity increases

Engineering Contradiction:

Improvetargeted protectionVSAvoidtreatment complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent merges two distinct therapeutic functions into a single bifunctional molecule: (1) antigen-specific binding through the antibody portion that recognizes glomerular basement membrane proteins, and (2) complement modulation through the attached complement regulatory protein. This consolidation achieves targeted protection while simplifying the treatment approach compared to using separate agents, as the molecule self-targets to glomeruli and provides localized complement inhibition in one unified therapeutic entity.

Inventive Principle:

Principle #5Merging (Combining)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The therapy effectively localizes to the kidney glomeruli, reducing inflammation and preventing further kidney damage, thereby slowing disease progression and ameliorating symptoms of glomerular diseases.

Implementation Method 1

a glomerular targeting moiety which is an antibody that binds to a Robo2 protein, an antibody that binds to a COL4A3 protein, an antibody that binds to a COL4A4 protein, or an antibody that binds to a COL4A5 protein

Methodology Applied

Scientific EffectAntibody-antigen binding: